Biopharmaceutical Expert Yujing Yang, Ph.D., New Director of Purification Technologies at Sartorius Stedim Biotech North America Inc.GOETTINGEN, Germany/Bohemia & NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- Dr. Yujing Yang recently assumed the position of Director of Purification Technologies, North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. . He brings broad experience in all areas of biopharmaceutical downstream processing Downstream processing refers to the recovery and purification of biosynthetic products, particularly pharmaceuticals, from natural sources such as animal or plant tissue or fermentation broth, including the recycling of salvageable components and the proper treatment and disposal and in-depth knowledge of biotech-related technologies, such as Xflow filtration and membrane chromatography, to Sartorius Stedim Biotech (Paris:DIM). In his current position, Dr. Yang reports to Dr. Uwe Gottschalk, Vice President of Marketing, Purification Technologies. Dr. Yang obtained both his Bachelor's and Master's degrees in Engineering from Tsinghua University History Tsinghua University was established in Beijing in 1911 on the site of a former royal garden belonging to a prince, and was funded by an indemnity which in Beijing, China, and earned his Ph.D. in Environmental Biology at the University of Massachusetts The system includes UMass Amherst, UMass Boston, UMass Dartmouth (affiliated with Cape Cod Community College), UMass Lowell, and the UMass Medical School. It also has an online school called UMassOnline. in Boston, where he conducted research on cloning and won a number of awards. Before joining Sartorius Stedim Biotech, Dr. Yujing Yang was Industrial Commercial Leader for Life Sciences in Greater China at GE Healthcare GE Healthcare is a $18 billion (USD) unit of General Electric (GE). It employs more than 46,000 people worldwide and is headquartered in Chalfont St. Giles, Buckinghamshire, United Kingdom. GE Healthcare is the first GE business segment headquartered outside the United States. , where he was responsible for marketing, sales and support teams. Prior to assuming this position, he was Technical Marketing Director for Asia, and held various positions in business development, product management, application and technical support. Dr. Yang, who has been working in the field of biopurification for twelve years, was employed in various management and research positions at Pall Corporation Pall Corporation NYSE: PLL, formerly Micro Metallic Company, is an East Hills, New York based global business in the diverse field of filtration, separations and purification. Total revenues for fiscal 2006 were $2 billion, with over 11,000 employees and $56. , the U.S. National Research Council and the Boston Biomedical Research Biomedical research (or experimental medicine), in general simply known as medical research, is the basic research or applied research conducted to aid the body of knowledge in the field of medicine. Institute. He also taught as an Assistant Professor for three years at Tsinghua University and has four bioprocessing patents to his name. Current image file: Dr. Yujing Yang, Director of Purification Technologies, North America, at Sartorius Stedim Biotech. http://www.sartorius-stedim.com/media/content/press/support/Yujing_Yang.jpg A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. For next-generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions" on a daily basis. Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris Euronext Paris is France's securities market, formerly known as the Paris Bourse, which merged with the Amsterdam and Brussels exchanges in September 2000 to form Euronext NV, which is the second largest exchange in Europe behind the London Stock Exchange. . With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs over 2,300 people, and in 2008 generated sales revenue of 368.0 million euros. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion